Heart Failure

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes

Top

Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjörnsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012 Aug 16. Epub ahead of print. The aim of this study was to examine the relationship between glycaemic control and hospitalisation for heart failure in patients with type 2 diabetes.

Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients

Top

Mukerji R, Petruc M, Fresen JL, Terry BE, Govindarajan G, Alpert MA. Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients. Am J Cardiol. 2012;110(3):415-419. To assess the effect of weight loss on ventricular repolarization in morbidly obese patients, 39 normotensive subjects whose baseline body mass indexes were ≥40 kg/m2 before weight loss from bariatric surgery were studied.

Assessing Vascular Disease Risk Associated with Medication-Related Hypoglycemia

Top

Exclusive! Expert video from Burton E. Sobel, MD, on the debate over intensive vs somewhat less intensive glycemic control in the context of this study. Zhao Y, Campbell CR, Fonseca V, Shi L. Assessing Vascular Disease Risk Associated with Medication-Related Hypoglycemia. Diabetes Care. 2012;35(5):1126-1132. Zhao and colleagues examined the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk among veterans with type 2 diabetes in a retrospective cohort study.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial

Top

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes an analysis of baseline data from the ORIGIN trialRamachandran A, Riddle MC, Kabali C, Gerstein HC for the ORIGIN Investigators. Diabetes Care. 2012 35 749 753. The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial is a global trial assessing whether targeting normal FPG levels with basal insulin glargine reduces cardiovascular outcomes compared with standard care among people taking 0 or 1 oral antidiabetes drugs (OADs).

Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD)

Top

McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, Mangione CM, Herman WH. Diabetes Care. Predictors of mortality over 8 years in type 2 diabetic patients Translating Research Into Action for Diabetes (TRIAD). 2012 Mar 19. Epub ahead of print. To examine demographic, socioeconomic, and biological risk factors for all-cause, cardiovascular, and noncardiovascular mortality in patients with type 2 diabetes over 8 years and to construct mortality prediction equations.

The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study

Top

Seaquist ER, Miller ME, Bonds DE for the ACCORD Investigators. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care. 2012 35(2) 409 414.  Seaquist and colleagues examined data from an Action to Control Cardiovascular Risk in Diabetes (ACCORD) substudy to explore the relationship between frequent and unrecognized hypoglycemia and mortality.

Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus

Top

Ai M, Otokozawa S, Schaefer EJ, et al. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin Chimica Acta.. 2009;406(1-2):71-74. Diabetes mellitus is a major risk factor for coronary heart disease (CHD), renal failure, retinopathy, and neuropathy. Lowering glycosylated hemoglobin (HbA1c) as well as low-density lipoprotein-cholesterol (LDL-C) has been associated with a decreased risk of these complications.

1 2 3 4 5 6 Next